Aldeyra shoots up on news of AbbVie deal

2 November 2023

US ophthalmic drug developer Aldeyra Therapeutics (Nasdaq: ALDX) saw its shares leap 48.5% to $2.54 yesterday after it announced the signing of a deal with pharma major AbbVie (NYSE: ABBV).

Under the terms of the accord, AbbVie has the option to acquire a co-exclusive license to develop, manufacture, and commercialize Aldeyra’s reproxalap in the USA and an exclusive license to develop, manufacture, and commercialize reproxalap outside the USA.

Reproxalap could help replace AbbVie’s sales of its dry eye disease drug Restasis (cyclosporine ophthalmic emulsion), which continue to slide following the first generic approval in February 2022.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK